Overview

NICE is unable to make a recommendation on depemokimab (Exdensur) for treating chronic rhinosinusitis with nasal polyps in adults. This is because the company did not provide an evidence submission.

Last reviewed: 22 January 2026

Next review: We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance